The Analyst Landscape: 7 Takes On Alkermes
During the last three months, 7 analysts shared their evaluations of Alkermes (NASDAQ:ALKS), revealing diverse outlooks from bullish…
Alkermes Unveils Phase 1b Data for Narcolepsy Treatment at SLEEP 2024
Alkermes plc (NASDAQ:ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
PRNewswire
– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and
6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of…
7 Analysts Assess Alkermes: What You Need To Know
Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from…
Alkermes’ Sleeping Disorder Studies’ Data Look Excellent, Analyst Says
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.
Breaking Down Alkermes: 5 Analysts Share Their Views
In the last three months, 5 analysts have published ratings on Alkermes (NASDAQ:ALKS), offering a diverse range of…
Alkermes Shares Long-Term LYBALVI Treatment Data for Schizophrenia at SIRS 2024 Congress
Alkermes plc (NASDAQ:ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7,
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell
• Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Alkermes’s Earnings Outlook
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here’s what investors need…